119 research outputs found
Somdet Phra Phutthachan (To)
No full textThe author summarizes the biography of Somdet Phra Phutthachan (To), a well-respected monk who lived between the reign of King Rama I and King Rama IV. For most people, the monk was widely known for his amulets, while the author argues that he was a sage in teaching lay people and dealing with the state intervention into the Sangha
Somdet Phrachaoborommawongthoe Kromphraya Sudarattanaratchaprayun prathap bon tang
No full textThe author presents an old photograph of Somdet Phrachaoborommawongthoe Kromphraya Sudarattanaratchaprayun, a daughter of King Rama III. This picture was taken by King Rama V in 1868. The author uses this picture as an evidence to claim that another picture of the same women which is almost identical to this one was also taken by King Rama V at about the same time
Somdet Phrachaoborommawongthoe Kromphraya Sudarattanaratchaprayun prathap bon phra kao-ai
No full textThe author presents an old photograph which he speculates that it was taken by King Rama V in 1868. The author took a copy of the picture from the book regarding the evolvement of Thai customs during the early Rattanakosin period. The photograph portrays Somdet Phrachaoborommawongthoe Kromphraya Sudarattanaratchaprayun, a daughter of King Rama III, was sitting on a modern style chair. In addition to describing a style of dress wore by this royal woman, the author also briefly describes her biography
Somdet Phramahasamana Chao Krom Phraparamanuchitchinorot song phraniphon ""Sanphasit kamchan"" set mua dai
No full textDrawing on historical chronicles and history of Wat Phrachetuphon, the author argues that Somdet Phramahasamanachao Kromphraparamanuchitchinorot completed composing Sapphasit Kamchan during 1834-1835. Sapphasit Kamchan is a poetical tale based on the stories of Lord Buddha's reincarnation
Determinants of removal and reappearance in plasma non-transferrin bound iron
No full textTransferrin is a plasma iron transport protein responsible for binding iron released from the breakdown of red cells in macrophages and delivering this iron to developing red cells in the bone marrow. In health, about one-third of the two iron binding sites on transferrin molecules are saturated with iron. In iron overload, transferrin becomes fully saturated and iron is found in the plasma in forms which are not bound to transferrin, defined as nontransferrin bound iron (NTBI). In this thesis, the factors which determine the appearance and removal of NTBI have been examined. The effects of iron chelation therapy with desferrioxamine (DFO) have been compared both in vivo and in vitro. In order to do this, a novel modification of an existing HPLC based assay system has been developed. This assay has been designed following the discovery during the work on this thesis of an in vitro 'shuttle' effect of iron between nitrilotriacetic acid (NTA) and DFO. This 'shuttle' leads to a falsely low measurement of NTBI, or a falsely fast apparent kinetic of NTBI removal, unless the free metal binding sites on DFO are blocked prior to the assay procedure. An aluminium blocking step has been developed whereby the remaining metal binding sites of DFO are blocked with an excess of aluminium prior to the NTBI assay. Using this approach, the kinetics of NTBI removal by DFO in vitro are relatively slow as is NTBI removal in vivo. NTBI removal by DFO is both concentration and time dependent but in iron overload NTBI removal is not complete at 10 μM DFO (a clinically relevant plasma concentration) even after 8 hours. Having defined the aluminium blocking method in vitro, the kinetics of NTBI removal by a variety of clinical DFO regimens has been examined. DFO levels have also been measured using a novel immunoassay system which measures the iron bound form of DFO, namely ferrioxamine (FO). The removal of NTBI with 8 hour subcutaneous infusions of DFO (standard therapy) has been compared with NTBI removal with twice daily intramuscularly DFO boluses. Surprisingly, these studies suggest that NTBI removal as quantitated by reduction in the area under the curve is as efficient with the bolus regimen as 8 hour subcutaneous infusions. The kinetics of NTBI removal have been also examined with prolonged intravenous DFO therapy and suggest that NTBI removal may not be possible with conventional intravenous therapy. In a further study, the kinetics of removal with long acting depot DFO have been compared with NTBI removal with conventional therapy. The effects of a novel polymeric form of DFO (HES- DFO) on NTBI removal have been examined which suggest that this form of DFO may result in significant quantities of loosely bound and potentially toxic forms of iron building up in plasma
Suan pa Sirikit thanakhan phanmai
No full textThe author introduces Suan Pa Somdet Phranangchao Sirikit Phraborommarachini, the botanical garden of central region. It is located in Ratchaburi province
Selection of drug resistant mutants from random library of <it>Plasmodium falciparum </it>dihydrofolate reductase in <it>Plasmodium berghei </it>model
No full textAbstract Background The prevalence of drug resistance amongst the human malaria Plasmodium species has most commonly been associated with genomic mutation within the parasites. This phenomenon necessitates evolutionary predictive studies of possible resistance mutations, which may occur when a new drug is introduced. Therefore, identification of possible new Plasmodium falciparum dihydrofolate reductase (PfDHFR) mutants that confer resistance to antifolate drugs is essential in the process of antifolate anti-malarial drug development. Methods A system to identify mutations in Pfdhfr gene that confer antifolate drug resistance using an animal Plasmodium parasite model was developed. By using error-prone PCR and Plasmodium transfection technologies, libraries of Pfdhfr mutant were generated and then episomally transfected to Plasmodium berghei parasites, from which pyrimethamine-resistant PfDHFR mutants were selected. Results The principal mutation found from this experiment was S108N, coincident with the first pyrimethamine-resistance mutation isolated from the field. A transgenic P. berghei, in which endogenous Pbdhfr allele was replaced with the mutant PfdhfrS108N, was generated and confirmed to have normal growth rate comparing to parental non-transgenic parasite and also confer resistance to pyrimethamine. Conclusion This study demonstrated the power of the transgenic P. berghei system to predict drug-resistant Pfdhfr mutations in an in vivo parasite/host setting. The system could be utilized for identification of possible novel drug-resistant mutants that could arise against new antifolate compounds and for prediction the evolution of resistance mutations.</p
- …
